GCM
ATOS icon

Graham Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Graham Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,091
Closed -$125K – 1161
2025
Q4 		$125K Buy
14,091
+3,061
+28% +$38.7K ﹤0.01% 1124
2025
Q3 		$143K Buy
+11,030
New +$136K ﹤0.01% 1124
2022
Q1 		– Sell
-4,874
Closed -$116K – 894
2021
Q4 		$116K Buy
+4,874
New +$178K ﹤0.01% 500

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Graham Capital Management's ATOS Position: Q1 2026 in Review

Graham Capital Management sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 14,091 shares — an estimated $125K sold.

Graham Capital Management first reported a position in ATOS in Q4 2021 and held it in 3 quarters. The position peaked at $143K in Q3 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

  • Graham Capital Management reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Graham Capital Management sold 14,091 Atossa Therapeutics shares in Q1 2026, an estimated $125K.
  • Graham Capital Management first reported a position in Atossa Therapeutics in Q4 2021 and held it in 3 quarters.
  • Graham Capital Management's Atossa Therapeutics position peaked at $143K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Graham Capital Management's 13F filing for Q1 2026, filed 15 May 2026.